Stefan Stahl
Overview
Explore the profile of Stefan Stahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
2093
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hjelm L, Leitao C, Stahl S, Lofblom J, Lindberg H
Cold Spring Harb Protoc
. 2023 Jul;
2024(11):pdb.prot108399.
PMID: 37491080
Affibody molecules are small (6-kDa) affinity proteins generated by directed evolution for specific binding to various target molecules. The first step in this workflow involves the generation of an affibody...
12.
Leitao C, Hjelm L, Stahl S, Lofblom J, Lindberg H
Cold Spring Harb Protoc
. 2023 Jul;
2024(11):pdb.prot108400.
PMID: 37491079
Affibody molecules are small (6-kDa) affinity proteins generated by directed evolution for specific binding to various target molecules. The first step in this workflow involves the generation of an affibody...
13.
Stahl S, Hjelm L, Leitao C, Lofblom J, Lindberg H
Cold Spring Harb Protoc
. 2023 Jul;
2024(11):pdb.prot108398.
PMID: 37491078
Affibody molecules are small (6-kDa) affinity proteins folded in a three-helical bundle and generated by directed evolution for specific binding to various target molecules. The most advanced affibody molecules are...
14.
Meister S, Parks L, Kolmar L, Borras A, Stahl S, Lofblom J
Biotechnol J
. 2023 Jul;
18(11):e2200625.
PMID: 37448316
Due to their ability to catalytically cleave proteins and peptides, proteases present unique opportunities for the use in industrial, biotechnological, and therapeutic applications. Engineered proteases with redesigned substrate specificities have...
15.
Leitao C, Stahl S, Lofblom J
Methods Mol Biol
. 2023 Jul;
2681:99-112.
PMID: 37405645
This review describes the principles for generation of affibody molecules using bacterial display on the Gram-negative Escherichia coli and the Gram-positive Staphylococcus carnosus, respectively. Affibody molecules are small and robust...
16.
Leitao C, Borras A, Xu T, Oroujeni M, Liu Y, Westerberg C, et al.
J Control Release
. 2023 Mar;
357:185-195.
PMID: 36990160
Safety and efficacy of cancer-targeting treatments can be improved by conditional activation enabled by the distinct milieu of the tumour microenvironment. Proteases are intricately involved in tumourigenesis and commonly dysregulated...
17.
Leitao C, Borras A, Jonsson A, Malm M, Kronqvist N, Fleetwood F, et al.
Biochem Biophys Res Commun
. 2023 Mar;
655:75-81.
PMID: 36933310
Within the field of combinatorial protein engineering there is a great demand for robust high-throughput selection platforms that allow for unbiased protein library display, affinity-based screening, and amplification of selected...
18.
Hjelm L, Lindberg H, Stahl S, Lofblom J
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36614273
Affibody molecules are small affinity proteins that have excellent properties for many different applications, ranging from biotechnology to diagnostics and therapy. The relatively flat binding surface is typically resulting in...
19.
Borras A, Leitao C, Stahl S, Lofblom J
N Biotechnol
. 2022 Dec;
73:9-18.
PMID: 36526248
Conditional activation of engineered affinity proteins by proteolytic processing is an interesting approach for a wide range of applications. We have generated an anti-idiotypic masking domain with specificity for the...
20.
Rinne S, Yin W, Borras A, Abouzayed A, Leitao C, Vorobyeva A, et al.
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740315
Increasing evidence suggests that therapy targeting the human epidermal growth factor receptor 3 (HER3) could be a viable route for targeted cancer therapy. Here, we studied a novel drug conjugate,...